Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota

University Hospital, Gentofte, Copenhagen

Status: Completed

Conditions: Type 2 Diabetes

Treatments: Drug: Sevelamer 1600 mg TID for 7 days; Drug: Placebo 1600 mg TID for 7 days

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02061124

H-2-2013-148

Details and patient eligibility

About

Accumulating evidence suggests that bile acids and bacteria in our intestines may constitute essential components in the complex mechanisms regulating gut hormone secretion and glucose homeostasis. At the same time, bile acids and gut bacteria are interdependent. Thus, it is likely that modification of the enterohepatic circulation of bile acids can lead to changes in gut hormone secretion or gut bacteria composition and consequently affect glucose homeostasis.

The current study is a human interventional study with 7-day ingestion of a bile acid sequestrant or placebo, preceded and followed by meal tests and faecal sampling. The aim is to examine how (and if) bile acid sequestration can influence postprandial glucagon-like peptide-1 (GLP-1) secretion, gut microbiota and glucose homeostasis in patients with type 2 diabetes and healthy individuals. As a tool to sequester bile acids we will use sevelamer, a phosphate binding resin used in the treatment of hyperphosphataemia in adult patients with chronic kidney disease. Surprisingly, sevelamer was recently shown to improve glycaemic control in patients with chronic kidney disease and type 2 diabetes.

The investigators hypothesize that higher luminal concentrations of bile acids in the distal gut will elicit changes in the postprandial gut hormone secretion and gut bacteria composition. The current study will help to clarify this hypothesis and improve our general understanding of the association between bile acid circulation and signalling, gut hormone secretion, gut bacteria and glucose metabolism.

Enrollment: 50 patients

Sex: All

Ages: 35 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Both groups

• Caucasian ethnicity
• Normal haemoglobin
• Age above 35 years and below 80 years
• Informed and written consent
• BMI > 23 kg/m2 and <35 kg/m2

Patients with type 2 diabetes

• Type 2 diabetes for at least 3 months
• Diagnosed according to the criteria of the World Health Organization (WHO)

Healthy Subjects

• Normal fasting plasma glucose (FPG) <6.5 mM and
• Normal glycated haemoglobin (HbA1c) <6.0 %

Exclusion criteria

Both groups

• Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) >2 times normal values) or history of hepatobiliary disorder
• Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major intra-abdominal surgery
• Hypo- or hyperphosphataemia
• Nephropathy (serum creatinine >150 µM and/or albuminuria
• Treatment with medicine that cannot be paused for 12 hours
• Intake of antibiotics six months prior to study
• Hypo- or hypercalcaemia
• Hypo- and hyperthyroidism
• Treatment with oral anticoagulants
• Active or recent malignant disease
• Any treatment or condition requiring acute or sub-acute medical or surgical intervention
• Lack of effective birth control in premenopausal women
• Positive pregnancy test on study days in premenopausal women
• Tobacco smoking
• Any condition considered incompatible with participation by the investigators

Patients with type 2 diabetes

• Treatment with insulin
• Treatment with incretin-based therapy

Healthy Subjects

• Diabetes or
• prediabetes (fasting plasma glucose levels >6.5 mM or HbA1c >6.0%)
• First-degree relatives with diabetes

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 4 patient groups, including a placebo group

T2DM, sevelamer

Active Comparator group

Description:

Patients with type 2 diabetes treated with sevelamer

Treatment:

Drug: Sevelamer 1600 mg TID for 7 days

T2DM, placebo

Placebo Comparator group

Description:

Patients with type 2 diabetes treated with placebo

Treatment:

Drug: Placebo 1600 mg TID for 7 days

Healthy subjects, sevelamer

Active Comparator group

Description:

Healthy subjects treated with sevelamer

Treatment:

Drug: Sevelamer 1600 mg TID for 7 days

Healthy subjects, placebo

Placebo Comparator group

Description:

Healthy subjects treated with placebo

Treatment:

Drug: Placebo 1600 mg TID for 7 days